Cooperation between Fraunhofer IZI and Lipocalyx GmbH to develop new carrier systems for the gene-based treatment of inflammatory diseases

The Department of Drug Design and Target Validation at the Fraunhofer IZI is being awarded a €400,000 grant from the State of Saxony-Anhalt to develop new carrier systems for the gene-based treatment of inflammatory diseases. The project will be conducted in close collaboration with Lipocalyx GmbH based in Halle.

Broadly speaking, gene therapies seek to replace defective genes by either introducing healthy copies of the gene or inactivating defective gene products. In order to do this, corresponding gene sequences are delivered into the target cells which then regulate the production of the respective proteins at the translational level. Transporting the regulatory nucleic acids to the target cells is, however, no easy feat. Free nucleic acids are not usually absorbed by cells and are exposed to enzymes (nucleases) in biological fluids, which quickly break them down. Hence the need for molecular carrier systems to guide the nucleic acids to the point of action, delivering them into the target cells before releasing them.

So-called viromers present a highly promising solution here. Like other transporters, viromers form nanoparticles ranging between 100–500 nm in size and have nucleic acids packed inside them. Investigations carried out by Lipocalyx GmbH (www.viomer-transfection.com) have demonstrated high transfection efficiencies among immune cells, especially monocytes / macrophages and dendritic cells, when using the viomer technology.

The project will now go on to investigate the therapeutic potential of viromers as a carrier system, focusing on whether disease-relevant inflammatory mediators can be influenced by the transfection of regulatory DNA and / or RNA molecules. Using a model system for inflammatory joint diseases such as that for rheumatoid arthritis, viromers are to be identified that can be enhanced together with nucleic acids which specifically regulate inflammation, with the ultimate goal of developing a gene therapy.

It is generally expected that the development of new carrier systems for gene-based treatment concepts will close the gap between successful testing in vitro and efficacy in the disease model.
Fig.: central structural element of a viromer (blue: binding site for the nucleic acids that are to be transported | gray: alkyl chain for membrane mobility | red: carboxyl residues ensure the solubility of the structure and act as a pH sensor)
The Fraunhofer Institute for Cell Therapy and Immunology IZI investigates and develops solutions to specific problems at the interfaces of medicine, life sciences and engineering. One of the institute’s main tasks is to conduct contract research for companies, hospitals, diagnostic laboratories and research institutes operating in the field of biotechnology, pharmaceuticals and medical engineering. The Fraunhofer IZI develops, optimizes and validates methods, materials and products for the business units Cell and Gene Therapy, Drugs, Diagnostics and Biosystems Technology. Its areas of competence lie in cell biology, immunology, drug biochemistry, biomarker, bioanalytics and bioproduction as well as process development and automation. In these areas, research specifically focusses on the indications oncology, neuropathology, autoimmune and inflammatory diseases as well as infectious diseases and regenerative medicine.

The Fraunhofer-Gesellschaft is the leading organization for applied research in Europe. Its research activities are conducted by 69 institutes and research units at locations throughout Germany. The Fraunhofer-Gesellschaft employs a staff of 24,500, who work with an annual research budget totaling 2.1 billion euros. Of this sum, 1.9 billion euros is generated through contract research. More than 70 percent of the Fraunhofer-Gesellschaft’s contract research revenue is derived from contracts with industry and from publicly financed research projects. International collaborations with excellent research partners and innovative companies around the world ensure direct access to regions of the greatest importance to present and future scientific progress and economic development.

Further contacts
Dr. Holger Cynis  I  Phone +49 345 131428-00  I  holger.cynis@izi.fraunhofer.de  I  Fraunhofer Institute for Cell Therapy and Immunology IZI, Leipzig, Germany  I  Department of Drug Design and Target Validation, Halle (Saale)  I  www.izi.fraunhofer.de